Consistency of patient versus investigator reporting of symptomatic adverse events (AEs) in international trials.

38Background: FDA approved 3 androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer (nmCRPC) based on global randomized trials with control arms of placebo + ADT. Despi...